Stepwise intensification of insulin therapy in Type 2 diabetes management-exploring the concept of the basal-plus approach in clinical practice

Diabetic Medicine

Volumn 30, Issue 3, 2013, Pages 276-288

  Owens, D R ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BASAL INSULIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; METFORMIN; ORAL ANTIDIABETIC AGENT; SHORT ACTING INSULIN; SULFONYLUREA; TRIMETOZINE; UNCLASSIFIED DRUG;

BLOOD GLUCOSE MONITORING; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN HYPOGLYCEMIA; INSULIN TREATMENT; LIFESTYLE MODIFICATION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; TREATMENT DURATION; WEIGHT GAIN;

DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULINS; POSTPRANDIAL PERIOD; PRACTICE GUIDELINES AS TOPIC;

EID: 84874160370     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12019     Document Type: Review

References (48)

1. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with Type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. J Am Med Assoc 1999; 281: 2005-2012.
2. Holman RR, Turner RC. A practical guide to basal and prandial insulin therapy. Diabet Med 1985; 2: 45-53.
3. Monnier L, Colette C, Dunseath GJ, Owens DR. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 2007; 30: 263-269.
4. Stolar M. Glycemic control and complications in type 2 diabetes mellitus. Am J Med 2010; 123: S3-S11.
5. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000; 321: 405-412.
6. Control Group, Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009; 52: 2288-2298.
7. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. Br Med J 2006; 332: 73-78.
8. Bonora E, Corrao G, Bagnardi V, Ceriello A, Comaschi M, Montanari P et al. Prevalence and correlates of postprandial hyperglycaemia in a large sample of patients with type 2 diabetes mellitus. Diabetologia 2006; 49: 846-854.
9. Riddle M, Umpierrez G, DiGenio A, Zhou R, Rosenstock J. Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes. Diabetes Care 2011; 34: 2508-2514.
10. International Diabetes Federation. Guideline for Management of Postmeal Glucose. 2007. Available at http://www.idf.org/webdata/docs/Guideline_PMG_final.pdf Last accessed 8 February 2012.
11. Monnier L, Colette C, Owens D. Postprandial and basal glucose in type 2 diabetes: assessment and respective impacts. Diabetes Technol Ther 2011; 13: S25-S32.
12. Ceriello A. The management of postprandial glucose. US Endocrinol 2008; 4: 63-67.
13. Nolan JJ. Consensus guidelines, algorithms and care of the individual patient with type 2 diabetes. Diabetologia 2010; 53: 1247-1249.
14. Vaag A, Lund SS. Insulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analogues. Eur J Endocrinol 2012; 166: 159-170.
15. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
16. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-3086.
17. Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009; 361: 1736-1747.
18. Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007; 357: 1716-1730.
19. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M et al. Management of hyperglycemia in Type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
20. Lankisch MR, Ferlinz KC, Leahy JL, Scherbaum WA, Orals Plus Apidra and LANTUS (OPAL) study group. Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral anti-diabetic drugs. Diabetes Obes Metab 2008; 10: 1178-1185.
21. Meneghini L, Mersebach H, Kumar S, Svendsen AL, Hermansen K. A comparison of two intensification regimens with rapid-acting insulin aspart in type 2 diabetes inadequately controlled by once-daily insulin detemir and oral antidiabetes drugs: the STEP-Wise randomized study. Endocr Pract 2011; 17: 727-736.
22. Barnett A, Begg A, Dyson P, Feher M, Hamilton S, Munro N. Insulin for type 2 diabetes: choosing a second-line insulin regimen. Int J Clin Pract 2008; 62: 1647-1653.
23. Raccah D, Bretzel RG, Owens D, Riddle M. When basal insulin therapy in type 2 diabetes mellitus is not enough-what next? Diabetes Metab Res Rev 2007; 23: 257-264.
24. Garber AJ. Premixed insulin analogues for the treatment of diabetes mellitus. Drugs 2006; 66: 31-49.
25. Ilag LL, Kerr L, Malone JK, Tan MH. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison. Clin Ther 2007; 29: 1254-1270.
26. Hedrington MS, Pulliam L, Davis SN. Basal insulin treatment in type 2 diabetes. Diabetes Technol Ther 2011; 13: S33-S42.
27. Jacober SJ, Scism-Bacon JL, Zagar AJ. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naive patients with type 2 diabetes receiving oral antidiabetes agents. Diabetes Obes Metab 2006; 8: 448-455.
28. Kazda C, Hulstrunk H, Helsberg K, Langer F, Forst T, Hanefeld M. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy. J Diabetes Complications 2006; 20: 145-152.
29. Malone JK, Bai S, Campaigne BN, Reviriego J, Augendre-Ferrante B. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes. Diabet Med 2005; 22: 374-381.
30. Malone JK, Kerr LF, Campaigne BN, Sachson RA, Holcombe JH. Lispro Mixture-Glargine Study Group. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther 2004; 26: 2034-2044.
31. Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005; 28: 260-265.
32. Lankisch M, Siegmund T, Ferlinz K, Scherbaum WA. Stepwise intensification of a basal insulin glargine regimen in patients close to the metabolic target (A1c 7.0-7.5%): is it worth adding a single daily injection of insulin glulisine? Subanalysis of the OPAL study. Diabetes 2009; 58: A2086-PO.
33. Owens DR, Luzio SD, Sert-Langeron C, Riddle MC. Effects of initiation and titration of a single preprandial dose of insulin glulisine while continuing titrated insulin glargine in Type 2 diabetes: a 6-month 'proof-of-concept' study. Diabetes Obes Metab 2011; 13: 1020-1027.
34. Davidson MB, Raskin P, Tanenberg RJ, Vlajnic A, Hollander P. A stepwise approach to insulin therapy in patients with type 2 diabetes mellitus and basal insulin treatment failure. Endocr Pract 2011; 17: 395-403.
35. Raccah D, Haak T, Huet D, Monnier L, Penfornis A, Robertson D et al. Stepwise intensification of prandial insulin versus basal-bolus insulin therapy in patients (pts) with Type 2 diabetes mellitus (T2DM). Diabetes 2010; 59: A555-P.
36. Kalergis M, Pacaud D, Strychar I, Meltzer S, Jones PJ, Yale JF. Optimizing insulin delivery: assessment of three strategies in intensive diabetes management. Diabetes Obes Metab 2000; 2: 299-305.
37. Group DS. Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial. Br Med J 2002; 325: 746.
38. Gross TM, Kayne D, King A, Rother C, Juth S. A bolus calculator is an effective means of controlling postprandial glycemia in patients on insulin pump therapy. Diabetes Technol Ther 2003; 5: 365-369.
39. Kaufman FR, Halvorson M, Carpenter S. Use of a plastic insulin dosage guide to correct blood glucose levels out of the target range and for carbohydrate counting in subjects with type 1 diabetes. Diabetes Care 1999; 22: 1252-1257.
40. Del Prato S, Nicolucci A, Vespasiani G. Optimising basal plus insulin therapy in type 2 diabetes by telecare assistance for self-monitoring of blood glucose - the ELEONOR study. Diabetologia 2008; 51: S452-S453.
41. Del Prato S, Nicolucci A, Lovagnini-Scher AC, Turco S, Leotta S, Vespasiani G. Telecare provides comparable efficacy to conventional self-monitored blood glucose in patients with type 2 diabetes titrating one injection of insulin glulisine-the ELEONOR study. Diabetes Technol Ther 2012; 14: 175-182.
42. Nicolucci A, Del Prato S, Vespasiani G. Optimizing insulin glargine plus one injection of insulin glulisine in type 2 diabetes in the ELEONOR study: similar effects of telecare and conventional self-monitoring of blood glucose on patient functional health status and treatment satisfaction. Diabetes Care 2011; 34: 2524-2526.
43. Riddle MC, Vlajnic A, Jones BA, Rosenstock J. Comparison of 3 intensified insulin regimens added to oral therapy for type 2 diabetes: twice-daily aspart premixed vs glargine plus 1 prandial glulisine or stepwise addition of glulisine to glargine. Diabetes 2011; 60: A0409-PP.
44. Riddle MC, Gao L, Vlajnic A. Clinical characteristics and outcomes of T2DM patients adding 1 to 3 stepwise prandial insulin doses to basal insulin and oral therapy: identifying a problematic subgroup. Diabetes 2012; 61: 14-OR.
45. Fritsche A, Larbig M, Häring H-U, The GINGER Study Group. A basal-bolus regimen of insulin glargine and insulin glulisine results in a lower rate of hypoglycaemia relative to endpoint HbA1c versus twice-daily premixed insulin in type 2 diabetes patients. Diabetologia 2010; 53: A573.
46. Rosenstock J, Ahmann AJ, Colon G, Scism-Bacon J, Jiang H, Martin S. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care 2008; 31: 20-25.
47. Fritsche A, Larbig M, Owens D, Häring HU, GINGER study group. Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study. Diabetes Obes Metab 2010; 12: 115-123.
48. Owens DR, van Schalkwyk C, Smith P, Beer S, Goenka N, Bain SC et al. Algorithm for the introduction of rapid-acting insulin analogues in patients with type 2 diabetes on basal insulin therapy. Pract Diabetes Int 2009; 26: 70-77.